W
William J. Tremaine
Researcher at Mayo Clinic
Publications - 290
Citations - 26053
William J. Tremaine is an academic researcher from Mayo Clinic. The author has contributed to research in topics: Ulcerative colitis & Inflammatory bowel disease. The author has an hindex of 80, co-authored 282 publications receiving 24233 citations. Previous affiliations of William J. Tremaine include University of Paris & Cedars-Sinai Medical Center.
Papers
More filters
Journal ArticleDOI
Risk of colorectal neoplasia in patients with primary sclerosing cholangitis
Edward V. Loftus,William J. Sandborn,William J. Tremaine,Douglas W. Mahoney,Alan R. Zinsmeister,Kenneth P. Offord,Lee J. Melton +6 more
TL;DR: If primary sclerosing cholangitis is an additional risk factor for neoplasia in ulcerative colitis, the clinical significance of the risk seems to be low.
Journal ArticleDOI
The fate of low grade dysplasia in ulcerative colitis
Thomas A. Ullman,Edward V. Loftus,Sanjay Kakar,Lawrence J. Burgart,William J. Sandborn,William J. Tremaine +5 more
TL;DR: Neoplastic progression in patients with UC and LGD is common and total proctocolectomy should be offered to all patients with flat LGD, illustrating numerous pitfalls in the practice of surveillance.
Journal ArticleDOI
Diet, but not oral probiotics, effectively reduces urinary oxalate excretion and calcium oxalate supersaturation.
John C. Lieske,William J. Tremaine,Claudio De Simone,Helen M. O'Connor,Xujian Li,Eric J. Bergstralh,David S. Goldfarb +6 more
TL;DR: It is suggested that dietary oxalate restriction is useful for kidney stone prevention and the tested probiotic preparations did not influence urinaryOxalate levels in patients on a restricted oxalates diet.
Journal ArticleDOI
Combination therapy with oral tacrolimus (FK506) and azathioprine or 6-mercaptopurine for treatment-refractory Crohn's disease perianal fistulae.
TL;DR: Combination therapy with oral tacrolimus and AZA or 6-mercaptopurine may be effective treatment for CD perianal fistulae and higher initial tacolimus doses increase the risk of nephrotoxicity without improving clinical response.
Journal ArticleDOI
A placebo-controlled trial of cyclosporine enemas for mildly to moderately active left-sided ulcerative colitis.
William J. Sandborn,William J. Tremaine,Kenneth W. Schroeder,Kenneth P. Batts,George M. Lawson,Betty L. Steiner,Jay M. Harrison,Alan R. Zinsmeister +7 more
TL;DR: Cyclosporine enemas administered in a dosage of 350 mg/day for 4 weeks are not efficacious in mildly to moderately active left-sided ulcerative colitis.